AstraZeneca will pay insitro $40 million up front, with up to about $1.46 billion in milestones to follow, for liver and heart targets. At 2.7% of the disclosed total, the upfront leaves most of the value tied to targets insitro has yet to deliver.
Perspective Coverage
5 publishers
- Builder
- Builder 27%
- Operator
- Operator 26%
- Investor
- Investor 47%
Reality
- Evidence62
- Adoption
- Not scored
- Hype gap+30
- Incentives
- Not scored
- Confidence68
Active learning chose the lab experiments that taught a model to predict C-H borylation sites
A research team used an active-learning loop to choose its C-H borylation experiments, then pinpointed the correct site in every test on unseen substrates. The work treats a shortage of experimental data as the real limit on predicting reactions.
Reality
- Evidence52
- Adoption
- Not scored
- Hype gap+12
- Incentives55
- Confidence48
Alphabet's Isomorphic Labs is in funding talks at a $40 billion valuation. Crypto Briefing put its prior mark near $17.5 billion, so the ask more than doubles the price of a drug designer that has yet to dose a patient.
Perspective Coverage
6 publishers
- Builder
- Builder 26%
- Operator
- Operator 17%
- Investor
- Investor 57%
Reality
- Evidence55
- Adoption25
- Hype gap+45
- Incentives55
- Confidence55
Danaher's first autonomous lab, at Abcam, is projected to lift yearly reagent output tenfold, from tens to hundreds, once at full capacity in early 2027. Danaher has disclosed no cost, so the reagent count it reports in 2027 is what the plan will be judged on.
Perspective Coverage
3 publishers
- Builder
- Builder 33%
- Operator
- Operator 32%
- Investor
- Investor 35%
Reality
- Evidence30
- Adoption
- Not scored
- Hype gap+40
- Incentives70
- Confidence60
buildOne report1 publisher PhAI Labs' JEPA-Anything outpredicts a standard JEPA in most tests across seven fields
PhAI Labs' JEPA-Anything splits a world model's prediction into several modules, cutting error 35% against a standard JEPA on a Pong task. Its reported comparisons use that one baseline, and its liver cancer pick has only lab and mouse data.
Reality
- Evidence40
- Adoption
- Not scored
- Hype gap+30
- Incentives
- Not scored
- Confidence35
buildOne report1 publisher Microsoft's Quine closes the loop between a biology model and the wet lab
Microsoft says its Quine system narrowed thousands of compounds to a pancreatic cancer shortlist in one weekend. For research-AI teams, the part to study is the harness that sends lab results back into the next question, and nobody has yet measured its value across cycles.
Reality
- Evidence35
- Adoption
- Not scored
- Hype gap+30
- Incentives65
- Confidence40
A Baylor College of Medicine team used a structure-prediction workflow called GluePlex to find where a molecular glue grips the protein VAV1 before any experiment showed it. A separate group later reached the same conclusion in the lab.
Reality
- Evidence72
- Adoption15
- Hype gap+8
- Incentives68
- Confidence62
AbbVie, argenx, Lundbeck and Takeda send antibody sequences to Ginkgo for a 10,000-antibody training set
AbbVie, argenx, Lundbeck and Takeda are founding a Ginkgo and Apheris consortium to build a standardized developability dataset of 10,000 antibodies. Ginkgo will oversee production and wet-lab testing of the whole set, with members due to see the first data in early 2027.
Reality
- Evidence40
- Adoption20
- Hype gap+20
- Incentives65
- Confidence45
The six clocks agreeing matters more than the years they report, because a drug that quiets an inflamed lung moves the same blood proteins whether or not it slows ageing anywhere else.
Perspective Coverage
3 publishers
- Builder
- Builder 45%
- Operator
- Operator 32%
- Investor
- Investor 23%
Reality
- Evidence42
- Adoption5
- Hype gap+45
- Incentives70
- Confidence62
Cellular Intelligence has added Bob Langer and Yann LeCun to its scientific advisory board. The $62m to $70m it has raised now has to take STEM-PD, the cell therapy Novo Nordisk dropped, through Phase 2.
Reality
- Evidence45
- Adoption15
- Hype gap+40
- Incentives65
- Confidence55
S32 led a $140M round that takes Basecamp Research's total funding to $225M since 2019. Two of the sixteen named backers, NVIDIA and Anthropic's Anthology Fund, are also partners on the dataset its models train on.
Perspective Coverage
3 publishers
- Builder
- Builder 30%
- Operator
- Operator 15%
- Investor
- Investor 55%
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+40
- Incentives75
- Confidence60
Medicine holds the public's one favourable view of AI while hospitals deploy it on notes
Seventy percent of American adults say they are more worried than excited about AI, and the one exception in the polling is scientific research and medicine. The fastest uptake inside medicine is administrative.
Reality
- Evidence42
- Adoption32
- Hype gap+18
- Incentives38
- Confidence45
Basecamp banks $140M on a gene atlas it built with Anthropic and Nvidia
The Series C funds a 28-billion-parameter model trained on more than 100 billion genes. Two of the partners who helped assemble that dataset, Nvidia and Anthropic's joint fund, are also in the round.
Reality
- Evidence28
- Adoption
- Not scored
- Hype gap+34
- Incentives72
- Confidence48
SynCraft edits molecules atom by atom instead of asking an LLM to write new SMILES
A new paper reports that a model predicting executable atom-level edits outperforms state-of-the-art baselines at generating synthesizable analogues with high structural fidelity, and that open-weight backends perform comparably to proprietary ones.
Reality
- Evidence45
- Adoption15
- Hype gap+20
- Incentives60
- Confidence42
Clinicians answer the AI cure-for-cancer claim with more than 100 brain tumour types
A Melbourne oncologist told the Guardian she doubts a cure for all cancer inside 10 years, and the clinicians who said so expect the real gains in diagnostics, pathology and treatment selection. Those are steps a budget can be written against.
Reality
- Evidence62
- Adoption30
- Hype gap+58
- Incentives55
- Confidence64
Feeding a classifier 4D movies of mitochondria lifts drug-mechanism accuracy from 56% to 75%
UC San Diego researchers treated cancer cells with 25 mitochondria-perturbing compounds, collected 40,000 single-cell 4D movies, and trained a model that sorted the drugs by mechanism with the labels withheld.
Reality
- Evidence62
- Adoption12
- Hype gap+24
- Incentives68
- Confidence55
buildOne report1 publisher Anthropic moves part of its biology work out of simulation and into a Bay Area wet lab
Life sciences head Eric Kauderer-Abrams confirmed the lab in a Reuters account, describing the split between in-house work and outside partners as ordinary biotech practice, while a spokesperson said the site is not there to discover drugs.
Reality
- Evidence42
- Adoption31
- Hype gap+28
- Incentives68
- Confidence46
The company's head of life sciences told Reuters that real lab work is still the final test in biology. Anthropic has not said which experiments the lab is running, and it has yet to run a clinical trial.
Perspective Coverage
5 publishers
- Builder
- Builder 28%
- Operator
- Operator 35%
- Investor
- Investor 37%
Reality
- Evidence55
- Adoption40
- Hype gap+30
- Incentives70
- Confidence57
Obvious Ventures led $20M behind Mithrl's promise of a 50% faster path to IND
The Series A funds a second-generation platform. The only measured result the company has attached to it is a benchmark of its own showing 45% fewer tokens than uncustomized frontier models. Tokens are a compute cost.
Reality
- Evidence32
- Adoption24
- Hype gap+42
- Incentives78
- Confidence60
James Zou's agent company read the results of tens of thousands of finished trials and found that drugs aimed at switch-like, cell-type-specific targets reached market about 48% more often. No experiment has tested that yet.
Reality
- Evidence58
- Adoption22
- Hype gap+32
- Incentives60
- Confidence62